Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Receivables (2024 - 2025)

Stoke Therapeutics has reported Receivables over the past 2 years, most recently at $7.9 million for Q4 2025.

  • For Q4 2025, Receivables rose 233.83% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $7.9 million, up 233.83%, while the annual FY2025 figure was $7.9 million, 233.83% up from the prior year.
  • Receivables for Q4 2025 was $7.9 million at Stoke Therapeutics, down from $10.8 million in the prior quarter.
  • Over five years, Receivables peaked at $10.8 million in Q3 2025 and troughed at $2.4 million in Q4 2024.